NeutroPhase

Type: Product

Name: NeutroPhase

First reported Jun 11 2013 - Updated Jun 11 2013 - 1 reports

NovaBay Pharmaceuticals Mid-Year Clinical Update

Clinical Results From Three Auriclosene Phase 2 Trials Expected in Second Half of This YearEMERYVILLE, Calif., June 11, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc., (NYSE:NBY), a clinical-stage biotechnology company focused on the topical, ... [Published Morningstar.com - Jun 11 2013]

Entities: NovaBay Pharmaceuticals Inc, Catheter, NeutroPhase, Phase II, Dermatology

First reported May 28 2013 - Updated May 29 2013 - 1 reports

NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal Health

Virbac Exercises Option to Develop Auriclosene for Use in Global Veterinary MarketsEMERYVILLE, Calif. and CARROS, France, May 28, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc., (NYSE: NBY), a clinical-stage biotechnology company focused on the ... [Published Street Insider - May 28 2013]

Entities: NovaBay Pharmaceuticals Inc, Virbac SA, Animal Health, NeutroPhase

First reported Mar 18 2013 - Updated Mar 18 2013 - 2 reports

NovaBay Pharmaceuticals Inc

NovaBay CEO Interviewed on RedChip Money Report on Fox Business News

- Dr. Ron Najafi Highlights Aganocide Anti-Infective Platform - - Increasing Bacterial Resistance Requires New Treatment Paradigm - EMERYVILLE, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- NovaBay$ Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company ... [Published GlobeNewswire - Mar 18 2013]

Entities: NovaBay Pharmaceuticals Inc, Phase IIb, Dermatology

Quotes

Dr. Ron Najafi, Chairman and CEO of NovaBay Pharmaceuticals, explained, "This is an important year for NovaBay. Each of our three auriclosene phase 2 clinical studies – in urology, dermatology, and ophthalmology – is expected to report data in the second half of 2013. We are excited that the differentiated products we are developing will positively impact patients' lives once approved."

NovaBay Pharmaceuticals Mid-Year Clinical Update [Published Morningstar.com - Jun 11 2013]

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."

NBY, DGICA, STV, MHR, RPT, CFNL Are Seasonally Ripe To Go Down In the Next Five Weeks [Published TradingCharts.com - Jun 11 2013]

...Ron Najafi, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals. "We look forward to continuing our collaboration with Virbac as it conducts additional studies using auriclosene."

NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal He ... [Published Street Insider - May 28 2013]

"The expanded partnership with a premier marketing organization such as Pioneer Pharma opens up the opportunity for NovaBay to provide NeutroPhase in multiple emerging markets in Southeast Asia" said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay...

NovaBay expands marketing partnership with Pioneer Pharma for NeutroPhase in select Asian market [Published PharmaBiz - Sep 17 2012]

More Content

sort by: Date \| Relevance
NovaBay Pharmaceuticals Mid-Year Clinical Update [Published Morningstar.com - Jun 11 2013]
NBY, DGICA, STV, MHR, RPT, CFNL Are Seasonally ... [Published TradingCharts.com - Jun 11 2013]
RedChip Issues Research Profile on NovaBay Phar... [Published GlobeNewswire: Advertising News - Jun 06 2013]
RedChip Issues Research Profile on NovaBay Phar... [Published Benzinga.com - Jun 06 2013]
NovaBay Pharma inks collaboration and license p... [Published PharmaBiz - May 29 2013]
Virbac Buys Rights to Develop NovaBay's Auriclo... [Published Genetic Engineering News - May 28 2013]
NovaBay Pharmaceuticals and Virbac Enter Into a... [Published Street Insider - May 28 2013]
NovaBay enrols first patient in BAYnovation glo... [Published PharmaBiz - Apr 10 2013]
NovaBay CEO Interviewed on RedChip Money Report... [Published GlobeNewswire - Mar 18 2013]
NovaBay CEO Interviewed on RedChip Money Report... [Published Stockwatch - Mar 18 2013]
NovaBay Pharma receives $2.6 million from partn... [Published PharmaBiz - Sep 28 2012]
NovaBay expands marketing partnership with Pion... [Published PharmaBiz - Sep 17 2012]
NovaBay's NeutroPhase(R) Used in New Therapeuti... [Published GlobeNewswire - Sep 13 2012]
NovaBay Pharmaceuticals to Present at Rodman & ... [Published GlobeNewswire - Sep 04 2012]